Michael Green, PhD, discusses a new method of assessing lymphoma subtypes utilizing the tumor microenvironment.
In an interview, Michael Green, PhD, associate professor of lymphoma/myeloma at The University of Texas MD Anderson Cancer Center in Houston, TX, discusses a novel method of identifying B-cell lymphoma traits called "lymphoMAPs" to assess response to chimeric antigen receptor (CAR) T-cell therapy.
Previous methods of molecularly characterizing lymphoma samples have primarily focused on the tumor B cells themselves. About 25 years ago, this was through cellular origin subtypes as a transcriptional program of the tumor cells, categorizing them into 2 groups. More recently, genetic classifiers have emerged, placing lymphomas into 5 or 6 different categories based on somatic mutations.
LymphoMAPs differ from these approaches because they entirely focused on the tumor microenvironment, or the the nontumor component of lymphomas. The tumor microenvironment includes lymphoid cells like T cells and NK cells, myeloid cells, and importantly, the endothelial and stromal cell compartments.
"In the past, we've missed these in our profiling efforts because we primarily used single-cell suspensions, which depleted these components," Green explained.
LymphoMAPS accounts for all cell types that are not the tumor and identifies reproducible patterns in how these are assembled into archetypical patterns across patients. Green and his fellow researchers discovered 3 major archetypes:
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen